Art. -Nr.: HY-16701

BV6

22 Cited Publications

Kundenbewertung

Based on 22 publication(s) in Google Scholar

BV6 is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family. BV6 shows an IC₅₀ of 7.2 μM in MTS assays in HCC193 cells. BV6 can be used in the research of endometrial cancer and endometriosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 1001600-56-1
Formel: C₇₀H₉₆N₁₀O₈
Molecular Weight:1205.57

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BV6 Chemical Structure

CAS. Nr.: 1001600-56-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (22)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IAP^[1]

Alle IAP Isoform-spezifische Produkte anzeigen :

In Vitro

BV6 (250 nM-30 μM, 24 h) induces apoptosis in HCC193 and H460 lung cancer cell lines in a concentration- and time-dependent manner. BV6 can also enhance the sensitivity of HCC193 and H460 cell lines to radiation^[1].
BV6 (1μM 24 h; 5 μM, 48 h) significantly sensitizes the cell to radiation (HCC193-DER=1.38, at 1 μM BV6; H460-DER=1.42, at 5 μM BV6)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HCC193 cells, H460 cells
Concentration:

250 nM, 500 nM, 1 μM, 3 μM, 5 μM, 10 μM, 20 μM, 30 μM
Incubation Time:

24 hours
Result:

Decreased cell survival percentage for HCC193 with an IC₅₀ of 7.2μM.
Decreased the cell viability of H460 cells by about 60% at 30 μM.

Western Blot Analysis^[1]

Cell Line:

HCC193 cells, H460 cells
Concentration:

0.25 μM, 0.5 μM, 1 μM, 5 μM
Incubation Time:

1, 14, 24 hours
Result:

Reduced the expression of cIAP1 within one hour and gradually decreased XIAP with increased incubation time for both cell lines.
Reduced the expression of cIAP1 with 0.25μM and gradually decreased XIAP with increasing concentration for both cell lines.

ELISA Assay^[1]

Cell Line:

HCC193 cells, H460 cells
Concentration:

1 μM, 5 μM
Incubation Time:

12 hours
Result:

Induced enhancement of the secretion of TNFα in HCC193 cells.
Did not enhance the secretion of TNFα in H460 cells.

In Vivo

BV6 (10 mg/kg, twice weekly for 4 weeks, i.p.) attenuated the intensity of IAPs expression^[2].
BV6 (10 mg/kg, twice weekly for 4 weeks, i.p.) reduces the total number of lesions and the percentage of Ki67-positive cells compared to the control^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female endometriosis mice modeling by estradiol valerate (HY-B0672) at the dosage 0.5 µg/mouse/week s.c injected (6 weeks of age, BALB/c)^[2].
Dosage:

10 mg/kg
Administration:

a single i.p. injection,twice weekly for 4 weeks
Result:

Attenuated the intensity of IAPs expression.

Chemical Information

CAS. Nr. 1001600-56-1
Appearance Solid
Molecular Weight 1205.57
Formel C₇₀H₉₆N₁₀O₈
Color White to off-white
SMILES

O=C(NCCCCCCNC([C@@H](NC([C@H](CCC1)N1C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)=O)C(C3=CC=CC=C3)C4=CC=CC=C4)=O)[C@@H](NC([C@H](CCC5)N5C([C@H](C6CCCCC6)NC([C@H](C)NC)=O)=O)=O)C(C7=CC=CC=C7)C8=CC=CC=C8
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (22)

All WB

Sort by:

Journal Impact Factor

Cell Mol Immunol

cFLIPS regulates alternative NLRP3 inflammasome activation in human monocytes. [Abstract]

2023 Oct;20(10):1203-1215. PMID: 37591930
Nat Commun

Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus. [Abstract]

2018 Mar 19;9(1):1136. PMID: 29555915

BV6 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Mar 19;9(1):1136. [Abstract]

Western Blot analysis of p52, p100, NIK, c-IAP2, Peli1, and HSP60 in total lysis of control and Peli1-knockdown M12 cells that pretreated with DMSO or smac mimetic BV6 for 4 h, and then stimulated with anti-CD40 (αCD40) at the indicated time points.

BV6 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Mar 19;9(1):1136. [Abstract]

Western Blot analysis of p52, p100, NIK, c-IAP2, Peli1, and HSP60 in total lysis of control and Peli1-knockdown M12 cells that pretreated with DMSO or smac mimetic BV6 for 4 h, and then stimulated with BAFF at the indicated time points.

BV6 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Mar 19;9(1):1136. [Abstract]

Analysis of Lys48 ubiquitination of NIK in control and Peli1-knockdown M12 cells that pretreated with DMSO or smac mimetic BV6 for 4 h, then left unstimulated or stimulated with anti-CD40 (αCD40) for 4 h in the presence of MG132.
Cell Death Differ

Ubiquitin-binding domain in ABIN1 is critical for regulating cell death and inflammation during development. [Abstract]

2022 Oct;29(10):2034-2045. PMID: 35430614
Cell Death Dis

Adipocyte-specific Mlkl knockout mitigates obesity-induced metabolic dysfunction by enhancing mitochondrial functions. [Abstract]

2025 Oct 6;16(1):683. PMID: 41053093
Cell Death Dis

Polarity protein AF6 functions as a modulator of necroptosis by regulating ubiquitination of RIPK1 in liver diseases. [Abstract]

2023 Oct 12;14(10):673. PMID: 37828052
J Orthop Translat

XAF1 promotes osteoclast apoptosis by antagonizing the XIAP-caspase axis. [Abstract]

2024 Jun 7:47:15-28. PMID: 38957269
J Med Chem

Discovery of a 1 H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease. [Abstract]

2025 Oct 23;68(20):21766-21785. PMID: 41077763
J Taiwan Inst Chem Eng

June 2022, 104394.
Biomater Adv

Etoposide-loaded lipopolymer nanoparticles promote Smac minetic activity against inhibitor of apoptosis protein for glioblastoma treatment. [Abstract]

2025 Jan 13:170:214185. PMID: 39879864
Neurobiol Dis

Therapeutic potential of a TrkB agonistic antibody for ischemic brain injury. [Abstract]

2019 Jul:127:570-581. PMID: 30981830
Chem Biol Interact

Formoterol, a clinically approved drug, inhibits ferroptosis by suppressing lipid peroxidation and attenuates APAP-induced acute liver injury. [Abstract]

2025 Sep 4:111724. PMID: 40914538
Mol Neurobiol

Myeloid TBK1 Deficiency Induces Motor Deficits and Axon Degeneration Through Inflammatory Cell Infiltration. [Abstract]

2021 May;58(5):2435-2446. PMID: 33439438
Biochim Biophys Acta Mol Basis Dis

Directed elimination of senescent cells attenuates development of osteoarthritis by inhibition of c-IAP and XIAP. [Abstract]

2019 Jun 26;1865(10):2618-2632. PMID: 31251987
iScience

The necroptosis-inducing pseudokinase mixed lineage kinase domain-like regulates the adipogenic differentiation of pre-adipocytes. [Abstract]

2022 Sep 19;25(10):105166. PMID: 36204273
Aging (Albany NY)

Ubiquitin-speciﬁc protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-β signaling-induced epithelial-mesenchymal transition. [Abstract]

2018 Oct 18;10(10):2783-2799. PMID: 30335615
J Cell Sci

FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation. [Abstract]

2019 May 20;132(10):jcs227777. PMID: 31028177
Exp Cell Res

Indole-3-carbinol ameliorates necroptosis and inflammation of intestinal epithelial cells in mice with ulcerative colitis by activating aryl hydrocarbon receptor. [Abstract]

2021 Jul 15;404(2):112638. PMID: 34015312
Research Square Preprint

2023 Aug 17.
University of Portland

2022.
Research Square Preprint

2021 Jul.
Research Square Preprint

2020 May.
bioRxiv

May 2, 2018.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (82.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.8295 mL

4.1474 mL

8.2948 mL

5 mM

0.1659 mL

0.8295 mL

1.6590 mL

10 mM

0.0829 mL

0.4147 mL

0.8295 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li W, et al. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. J Thorac Oncol. 2011 Nov;6(11):1801-9. [Content Brief]

[2]. Uegaki T, et al. Inhibitor of apoptosis proteins (IAPs) may be effective therapeutic targets for treating endometriosis. Hum Reprod. 2015 Jan;30(1):149-58. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.8295 mL	4.1474 mL	8.2948 mL	20.7371 mL
	5 mM	0.1659 mL	0.8295 mL	1.6590 mL	4.1474 mL
	10 mM	0.0829 mL	0.4147 mL	0.8295 mL	2.0737 mL
	15 mM	0.0553 mL	0.2765 mL	0.5530 mL	1.3825 mL
	20 mM	0.0415 mL	0.2074 mL	0.4147 mL	1.0369 mL
	25 mM	0.0332 mL	0.1659 mL	0.3318 mL	0.8295 mL
	30 mM	0.0276 mL	0.1382 mL	0.2765 mL	0.6912 mL
	40 mM	0.0207 mL	0.1037 mL	0.2074 mL	0.5184 mL
	50 mM	0.0166 mL	0.0829 mL	0.1659 mL	0.4147 mL
	60 mM	0.0138 mL	0.0691 mL	0.1382 mL	0.3456 mL
	80 mM	0.0104 mL	0.0518 mL	0.1037 mL	0.2592 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BV6

Apoptosis Compound Library

Anti-Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BV6

Alle IAP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (22)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BV6

Apoptosis Compound Library

Anti-Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BV6

Alle IAP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (22)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BV6 Related Classifications

HY-16701 Related Classifications